SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-010354
Filing Date
2021-05-03
Accepted
2021-05-03 17:17:52
Documents
5
Period of Report
2021-04-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 41523
2 ex99-1.htm EX-99.1 402771
3 ex99-2.htm EX-99.2 97685
4 ex99-3.htm EX-99.3 146255
5 ex99-4.htm EX-99.4 93734
  Complete submission text file 0001493152-21-010354.txt   783397
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 21884696
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences